Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Infections 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1COVID-19 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Adenocarcinoma Of Esophagus 1

Interventions

fludarabine phosphate 50Cyclophosphamide 50Mycophenolic Acid 36Cyclosporine 33Busulfan 33Whole-Body Irradiation 32Peripheral Blood Stem Cell Transplantation 31Antilymphocyte Serum 24fludarabine 21Cord Blood Stem Cell Transplantation 21Tacrolimus 20Cytarabine 19Filgrastim 18Melphalan 17Radiotherapy 15Methylprednisolone 13Methotrexate 13Thiotepa 10Granulocyte Colony-Stimulating Factor 10Etoposide 9Cyclosporins 7Azacitidine 7thymoglobulin 5sargramostim 5Idarubicin 5Clofarabine 5Arsenic Trioxide 5Transplantation 4Sirolimus 4Gemtuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anemia, Refractory, with Excess of Blasts × monalizumab × Clear all
NCT06892223 2025-03-24

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Istituto Clinico Humanitas

Phase 2 Recruiting
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡